Current role
Drug Manufacturers - Specialty & Generic · Healthcare
Evan Lippman
Equibles does not estimate personal net worth.
Get an email with a short summary when Teva Pharmaceutical Industries Ltd publishes a filing, an earnings call transcript or a press release.
Get TEVA alertsAbout Evan Lippman
The proxy statement of Teva Pharmaceutical Industries Ltd reports total compensation of $7,222,009 for Evan Lippman in fiscal 2025, including a base salary of $496,923. Teva Pharmaceutical Industries Ltd is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Teva Pharmaceutical Industries Ltd includes Richard Francis (CEO and Board Member), Eli Kalif (CFO), Amir Weiss (Chief Accounting Officer) and 6 others.
Affiliation history
-
Teva Pharmaceutical Industries Ltd (TEVA)
Proxy statement
CurrentStart not stated–present
Last confirmed March 31, 2026
Company network
Leadership on record at Teva Pharmaceutical Industries Ltd
- Richard Francis CEO, Board Member
- Eli Kalif CFO
- Amir Weiss Chief Accounting Officer
- Andrew Weil Chief Accounting Officer
- Abbas Hussain Board Member
- Chen Lichtenstein Board Member
- Dr. Sol J. Barer Board Member
- Nechemia (Chemi) J. Peres Board Member
- Prof. Varda Shalev Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Teva Pharmaceutical Industries Ltd (TEVA) | Executive Vice President, Business Development | $496,923 | $7,222,009 |
Recent activity
No call appearances or filed executive changes recorded yet.